IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Gregory P. Lewis et al.   Attorney Docket No: MEDN117116

Application No: 09/808,414   Group Art Unit: 2166

Filed: March 12, 2001

Title: METHOD AND SYSTEM FOR ACCESSING HEALTHCARE INFORMATION USING AN ANATOMIC USER INTERFACE

INFORMATION DISCLOSURE STATEMENT

Seattle, Washington 98101

June 20, 2001

TO THE COMMISSIONER FOR PATENTS:

Applicants are aware of the information listed in the attached form that may be material to the prosecution of the above-identified patent application.

1.   _x_   Copies of the listed patents marked with a dagger (†) are enclosed for the Examiner's use.

2.   _X_   This application relies, under 35 U.S.C. § 120, on the earlier filing date of prior Application No. 09/523,569, filed March 10, 2000. The references listed on the attached form were submitted to and/or cited by the Patent and Trademark Office in this prior application and, therefore, are not required to be provided in this application.

3.   _____   A concise explanation of the relevance of document I.D. No. _____ (which is not in the English language), as presently understood by the individual designated under 37 C.F.R. § 1.56(c) most knowledgeable about its content, is provided in an English abstract appended to said document.

4.   _____   This Information Disclosure Statement is being filed concurrently with the above-identified application.

5.   _X_   Pursuant to 37 C.F.R. § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the national application (other than a CPA), within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application, before the mailing date of a first Office Action on the merits, or before the mailing date of a first Office Action after the filing of an RCE.

-1-

6. ____ Pursuant to 37 C.F.R. § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in 37 C.F.R. § 1.97(b) but before the mailing date of a final action under 37 C.F.R. § 1.113, a Notice of Allowance under 37 C.F.R. § 1.311, or an action that otherwise closes prosecution, and is accompanied by:

    a. ____ a certification statement as specified in 37 C.F.R. § 1.97(e); or

    b. ____ the submission fee set forth in 37 C.F.R. § 1.17(p). Check No. _____ in the amount of $180.00 is enclosed.

7. ____ Pursuant to 37 C.F.R. § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a final action under 37 C.F.R. § 1.113, a Notice of Allowance under 37 C.F.R. § 1.311, or an action that otherwise closes prosecution, but before or simultaneous with payment of the issue fee. The Information Disclosure Statement is accompanied by a certification statement as specified in 37 C.F.R. § 1.97(e) and the submission fee set forth in 37 C.F.R. § 1.17(p). Check No. _____ in the amount of $180.00 is enclosed.

8. _X_ The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.18 which may be required during the entire pendency of the application, or credit any overpayment, to Deposit Account No. 03-1740. This authorization also hereby includes a request for any extensions of time of the appropriate length required upon the filing of any reply during the entire prosecution of this application. A copy of this document is enclosed.

Respectfully submitted,

CHRISTENSEN O'CONNOR
JOHNSON KINDNESS^PLLC

Barbara M. Level

Barbara M. Level
Registration No. 45,483
Direct Dial No. 206.695.1776

I hereby certify that this correspondence is being deposited with the U.S. Postal Service in a sealed envelope as first class mail with postage thereon fully prepaid and addressed to the Commissioner for Patents, Washington, D.C. 20231, on the below date.

    Date: <u>June 20, 2001</u>

BML/ws

MEDN\17116163.DOC
06/20/01 9:39 AM